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Abstract
Background: China has experienced several severe outbreaks of influenza over the past century: 1918, 1957, 1968,
and 2009. Influenza itself can be deadly; however, the increase in mortality during an influenza outbreak is also
attributable to secondary bacterial infections, specifically pneumococcal disease. Given the history of pandemic
outbreaks and the associated morbidity and mortality, we investigated the cost-effectiveness of a PCV7 vaccination
program in China from the context of typical and pandemic influenza seasons.
Methods: A decision-analytic model was employed to evaluate the impact of a 7-valent pneumococcal vaccine
(PCV7) infant vaccination program on the incidence, mortality, and cost associated with pneumococcal disease
during a typical influenza season (15 % flu incidence) and influenza pandemic (30 % flu incidence) in China. The
model incorporated Chinese data where available and included both direct and indirect (herd) effects on the
unvaccinated population, assuming a point in time following the initial introduction of the vaccine where the
impact of the indirect effects has reached a steady state, approximately seven years following the implementation
of the vaccine program. Pneumococcal disease incidence, mortality, and costs were evaluated over a one year time
horizon. Healthcare costs were calculated using a payer perspective and included vaccination program costs and
direct medical expenditures from pneumococcal disease.
Results: The model predicted that routine PCV7 vaccination of infants in China would prevent 5,053,453 cases of
pneumococcal disease and 76,714 deaths in a single year during a normal influenza season.The estimated
incremental-cost-effectiveness ratios were ¥12,281 (US$1,900) per life-year saved and ¥13,737 (US$2,125) per
quality-adjusted-life-year gained. During an influenza pandemic, the model estimated that routine vaccination with
PCV7 would prevent 8,469,506 cases of pneumococcal disease and 707,526 deaths, and would be cost-saving.
Conclusions: Routine vaccination with PCV7 in China would be a cost-effective strategy at limiting the negative
impact of influenza during a typical influenza season. During an influenza pandemic, the benefit of PCV7 in
preventing excess pneumococcal morbidity and mortality renders a PCV7 vaccination program cost-saving.
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Background
Over the past century, China has experienced severe out-
breaks of influenza in 1918, 1957, 1968, and 2009. Influenza
itself can be deadly; however the increase in mortality dur-
ing an influenza outbreak is also attributable to secondary
bacterial infections, specifically pneumococcal disease. Dur-
ing the 1918 influenza pandemic, investigators at the time
concluded that the majority of deaths related to the influ-
enza outbreak were ultimately caused by complications
stemming from a secondary bacterial pneumonia infection
[1] and subsequent research has provided support for this
initial finding [2]. The 1918 pandemic, however, occurred
in an era prior to the use of antibiotics so the proportion of
influenza related deaths that were attributed to secondary
bacterial infection during that pandemic may overstate the
expected impact of pneumococcal infection related deaths
during a modern influenza pandemic outbreak. Evidence
regarding more recent pandemic outbreaks of influenza,
however, suggest that mortality due to secondary bacterial
infection remains a primary cause of death for individuals
initially suffering from influenza, even during an era where
antibiotics are in widespread use. An examination of the
1957 and 1968 pandemics in the U.S. found results similar
to the study of the 1918 pandemic [2]. Additionally, a study
investigating the 2009 H1N1 influenza outbreak found, by
examining autopsy reports, that evidence of bacterial pneu-
monia was detected in approximately 55 % of influenza re-
lated mortality cases [3]. The influenza vaccine remains the
primary method of protection against influenza among in-
dividuals and a possible pandemic outbreak amongst the
population. However, given the associated morbidity and
mortality attributed to secondary pneumococcal infections,
it is important to investigate possible alternative measures
that can be taken in order to help mitigate some of the
negative health consequences associated with influenza.
The 7-valent pneumococcal conjugate vaccine (PCV7)
was approved for use in the U.S. in 2000 and has been
recommended by the U.S. Centers for Disease Control
and Prevention (CDC) to be included in the routine
vaccination schedule for all infants in the U.S. [4]. In
the years subsequent to its inclusion into the routine
vaccination schedule of the U.S., there has been a sub-
stantial impact on the incidence of pneumococcal re-
lated diseases, largely attributed to the indirect effect of
herd protection on the unvaccinated child and adult
populations [5, 6]. A recent report by the CDC has
suggested that the majority of the reductions in invasive
pneumococcal disease (IPD) following the widespread
use of the PCV7 vaccine in the U.S. were due to the
indirect effect on the unvaccinated population by redu-
cing the nasopharyngeal carriage of Streptococcus pneu-
monia among immunized children [7]. As a result of the
effectiveness of the PCV7 vaccine since its introduction in
2000, the World Health Organization has recommended
the inclusion of PCV7 in childhood vaccination programs
worldwide [8].
In this study, we examined the public health and eco-
nomic impact of including PCV7 into the routine
immunization program in China in the context of both a
typical influenza season and a severe influenza pan-
demic. Although there are higher valency pneumococcal
vaccines available on the market in the U.S. and else-
where, the 7-valent pneumococcal conjugate vaccine is
currently the only pneumococcal vaccine approved for
use in China. As a result, we focused our study on the
potential inclusion of PCV7 into the Chinese national
immunization program. The PCV7 vaccine contains
seven serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F, which
accounts for approximately 76 % of the serotypes associ-
ated with pneumococcal disease among children less
than five years of age in China [9]. Given the effective-
ness of the PCV7 vaccine in reducing incidence of
pneumococcal disease in both the vaccinated and unvac-
cinated populations due to herd protection, and the link
between influenza and mortality due to secondary
pneumococcal infection, it is plausible that routine vac-
cination of infants with PCV7, either with or without
the use of the influenza vaccine, may help reduce the
morbidity and mortality associated with influenza during
both a typical influenza season and a potential severe in-
fluenza pandemic.
Methods
We adapted a previously developed decision-analytic model
of pneumococcal disease incidence and outcomes [10] to
assess the impact of incorporating the 7-valent pneumococ-
cal vaccine (PCV7) into the childhood vaccination schedule
during both a typical influenza season and an influenza
pandemic in China relative to the disease burden that
would exist in the absence of a pneumococcal vaccination
program. The model only included cases of pneumococcal
disease and pneumococcal related deaths. Morbidity and
mortality from influenza without pneumococcal co-
infection were not considered. In order to simulate a single
season, outcomes were assessed as a cross-sectional analysis
over a one-year period which was assumed to have oc-
curred after the vaccine indirect (herd) effects have reached
a steady state, approximately seven years following the ini-
tial introduction of the vaccine. Incremental costs, life-
years, and quality-adjusted life-years estimated by the
model reflect the lifetime consequences of events that
occur during this one-year period. All future costs and
health outcomes were discounted using a 3 % annual dis-
count rate. All cost-effectiveness results were calculated
from a payer perspective and only include direct medical
costs associated with treatment for pneumococcal related
disease as well as the cost of the vaccine and the direct cost
associated with administering the vaccine. All costs were
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reported using 2011 Chinese Yuan. In order to facilitate
comparisons with previously published cost-effectiveness
studies on the PCV7 vaccine, cost-effectiveness results were
also reported in U.S. dollars using exchange rates as of July
2011 (1 USD= ¥6.465) [11].
Model structure
The clinical starting point of the model is the choice of
vaccination strategy where the model compares the
case of no vaccines being administered to a case with a
vaccination coverage rate of 85 % among all children
less than two years of age in China over a one-year
period. Individuals within the model could be vacci-
nated or unvaccinated, depending on the vaccination
strategy and age group. All individuals are considered
at risk of developing influenza, may or may not receive
treatment for this illness, and may subsequently de-
velop a secondary pneumococcal related disease. The
pneumococcal disease states incorporated into the
model include invasive disease cases of meningitis and
bacteremia caused by Streptococcus pneumoniae, all-
cause inpatient pneumonia, and acute otitis media. In-
cidence rates for pneumococcal disease states differ
depending on a variety of factors: the probability of in-
dividuals within the model entering into one of the
pneumococcal related disease states during the one-
year period is determined by the initial choice of vac-
cination strategy, if the individual has developed influ-
enza and whether they received treatment for that
influenza, and the age group to which the individual
belongs. Clinical outcomes within the model are as-
sumed to be mutually exclusive. Additionally, in order
to capture the full benefits of the vaccine, both the dir-
ect benefits among the vaccinated and the indirect
benefits accruing to the unvaccinated population as a
result of herd protection are included in the model.
Table 1 Input parameters
Parameter Age group (Years)
0 - < 2 2 - 4 5 - 17 18 - 49 50 - 64 65+
Annual Incidence Rates per 100,000
Pneumococcal meningitis 2.5 0.6 14.6 5.2 3.4 6.9
Pneumococcal bacteremia 4.8 4.7 48.8 16.7 9.2 36.0
All-cause inpatient pneumonia 4239 3830 664 164 443 3700
All-cause otitis media (per person) 0.22 0.23
Percent of Meningitis that results in deafness 13 % 13 % 6 % 13 % 13 % 13 %
Percent of Meningitis that results in disability 7 % 7 % 5 % 7 % 7 % 7 %
Case-fatality rates
Pneumococcal meningitis .083 .083 .088 .472 .636 .768
Pneumococcal bacteremia .115 .036 .024 .130 .177 .288
All-cause inpatient pneumonia .048 .004 .008 .045 .057 .100
Direct Efficacy of Vaccine
Pneumococcal meningitis 73.5 % 67.1 %
Pneumococcal bacteremia 73.5 % 67.1 %
All-cause inpatient pneumonia 16.9 % 22.9 %
All-cause otitis media 6.4 % 5.8 %
Indirect (herd) Effect of Vaccine
Pneumococcal meningitis 46.8 % 40.3 % 17.5 % 38.3 % 17.4 % 33.6 %
Pneumococcal bacteremia 46.8 % 40.3 % 17.5 % 38.3 % 17.4 % 33.6 %
All-cause inpatient pneumonia 30.0 % 9.0 % 9.0 % 12.0 % 9.0 % 8.0 %
All-cause otitis media 20.1 % 19.0 %
Cost (¥) per Case of Pneumococcal Disease
Pneumococcal meningitis 24347 14805 24660 21825 21331 34495
Pneumococcal bacteremia 24347 14805 24660 21825 21331 34495
All-cause inpatient pneumonia 4416 2466 2867 8237 10517 14493
All-cause otitis media 148 136
All values measured in 2011 Chinese Yuan
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Model parameters and input data
The primary input parameters used in the model estima-
tion, broken down by age group, are presented in Table 1
and are briefly described in the following sections.
Population and coverage rates
A total population of 1.34 billion was assumed for the
model based on data from the Ministry of Health PRC
2009 Chinese Health Statistical Annual Report for 2010
[12]. This population was stratified into six age groups
(<2, 2 to 4, 5 to 17, 18 to 49, 50 to 64, and 65 years of age
and older), approximately 1.1 % of which were assumed to
be children less than two years of age [12]. PCV7 is not
currently included in the national immunization schedule
in China and therefore the steady state level of vaccination
coverage that would exist, if included, is unknown. As a
result, we assumed an 85 % coverage rate that is roughly
consistent with observed levels of coverage in the U.S.
[13]. Each child under the age of two is assumed to have
received four doses of the vaccine in the current period
and children aged two to four years were assumed to have
been vaccinated at some point prior to the start of the
model. Consistent with previous literature, the model also
assumes that there is no protection beyond the fifth year
after vaccination [14, 15]. As a result, all children and
adults five years of age and older were considered unvac-
cinated within the model.
Disease incidence and case fatality rates
Baseline, age-specific disease incidence rates, case fa-
tality rates, and the probabilities of developing long-
term complications from pneumococcal meningitis
were primarily derived from published sources. In
many cases, these data were presented in age groups
that did not specifically match the age groups used in
this study. We combined these age groups using a
weighted average based on estimated population size.
Incidence and case fatality rates for pneumococcal
meningitis among children less than five years of age
were derived from a published meta-analysis [16, 17].
This estimate was adjusted to account for the probabil-
ity that the cause of the meningitis was something
other than pneumococcal infection, and to improve
the estimation of disease impact by age by using data
from a meta-analysis of international incidence rates
and estimates of the proportion of invasive pneumo-
coccal disease cases by age for children under five
years of age in Taiwan [17–19]. Incidence and case fa-
tality rates for IPD among individuals older than five
years of age were derived from estimates of incidence
from a cost-effectiveness study of lower-middle income
countries [17, 20]. The probability of developing long-
term complications from meningitis infection that re-
sult in deafness or disability were taken from a series
of published papers [10, 14, 15, 17]. Age specific inci-
dence and case fatality rates for inpatient pneumonia and
otitis media were derived from existing data [16, 17, 20–23]
with adjustments made to the age groups used in this study
as described previously.
Influenza
The cumulative influenza incidence rate over a one-year
period was based on calculations from the number of speci-
mens tested from patients with influenza like symptoms
and the number of specimens found to test positive for in-
fluenza type A or B estimated from World Health Organi-
zation’s influenza virological surveillance data for China
[24]. Weekly data were examined over a three year period
from week forty-nine of 2010 through week forty-eight of
2013 (the last available data at the time of the calculations).
These data provided an estimated one-year cumulative inci-
dence rate of 15 %. This methodology is similar to a previ-
ously published estimate for the annual influenza incidence
rate in the U.S. of 13 % using the Centers for Disease Con-
trol and Prevention’s weekly influenza surveillance data
[10]. Consistent with existing literature, it was assumed that
persons with influenza had a 7.7 % increased risk of devel-
oping pneumococcal disease relative to those without influ-
enza [10, 25], and that individuals treated for influenza
using antiviral medication were at 26.3 % lower risk of de-
veloping pneumococcal disease [10, 26, 27]. The proportion
of those with influenza who were considered to be treated
for influenza within the model was estimated to be 28.44 %
based on calculations using published sources on influenza
treatment in China [28, 29]. It was also assumed, consistent
with previous literature, that during a severe pandemic the
one-year cumulative influenza incidence rate would rise to
30 % and that there would be an increased risk of pneumo-
coccal disease, ranging from 1.4 times to 149 times greater
for bacteremic and inpatient pneumonia depending on the
age group, and an increased risk of mortality stemming
from pneumococcal disease relative to a typical influenza
season [10].
Vaccine efficacy and indirect effects
The vaccine efficacy and indirect effectiveness based on
the herd effects estimates used in the model for all age
groups are provided in Table 1. These estimates are
based on a previously published study [10]. In that study,
it was assumed that vaccination of children less than
two years of age would result in a direct reduction in the
probability of the child developing IPD based on the
published efficacy of the vaccine [10, 30]. It was also as-
sumed, consistent with published literature, that among
previously vaccinated children between the ages of two
and four years old that the direct benefits of the vaccine
begin to wane to a level 91 % of their initial efficacy and
that there is no direct protection remaining for children
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over the age of five years old [10, 14]. The estimated in-
direct (herd) effects were based on previously published
data in the U.S. that measured the herd effects as a percent
reduction in pneumococcal disease incidence [10, 23].
These estimates were derived by assuming that all reduc-
tions in incidence of pneumococcal infection not attribut-
able to direct vaccine efficacy were therefore the impact of
the indirect effectiveness of the vaccine.
Cost data
All cost data incorporated into the model are Chinese spe-
cific and were based on published sources and measured in
2011 Chinese Yuan. Cost estimates for the direct, per case
medical costs associated with pneumococcal infection by
age group are shown in Table 1. These costs were based on
a recent study that examined the cost-effectiveness of
PCV7 in Shanghai [23]. In that study, the direct medical
costs related to pneumococcal diseases were derived from
an examination of de-identified case records from the
Shanghai Board of Health Central Information Data Base
and were based on confirmed inpatient cases of pneumo-
coccal disease from hospitals in Shanghai during 2011. The
total costs per case by disease type (meningitis, bacteremia,
and all-cause pneumonia) and age group used in the model
include hospitalization fees, physician consultation fees,
diagnostic tests, operation fees, nursing fees, and medica-
tion expenses. The vaccine administration costs include the
cost per dose of the vaccine, assumed to be ¥860 per dose
based on published vaccine prices in Shanghai [31], and a
direct administration cost assumed to be ¥10 per dose [23].
Utility weights
Utility values used to calculate quality-adjusted-life-years
(QALYs) for various disease states were taken from pub-
lished sources and were incorporated into the model as a
one-time reduction in the QALY for each disease occur-
rence. The value of the one-time reductions used in the
model were 0.023 for meningitis, 0.0079 for bacteremia,
0.006 for hospitalized pneumonia, 0.004 for non-
hospitalized pneumonia, and 0.005 for otitis media [32].
Utility values for deafness (0.73) and disability (0.68) result-
ing from meningococcal complications were also derived
from published sources [33, 34] and were applied to the
remaining years of life expectancy for each case.
Analyses
The model provides estimates for each vaccination strat-
egy over a one-year period. Estimates were generated for
the number of pneumococcal disease cases, number of
deaths related to pneumococcal disease, number of esti-
mated life years saved, the quality-adjusted-life-years
(QALYs) gained, costs associated with pneumococcal
disease, and costs associated with the vaccination pro-
gram. Incremental cost-effectiveness ratios (ICERs) were
estimated as the cost-per–life-year saved and cost-per-
QALY gained for both a typical influenza season and a
pandemic influenza season. Life years saved as a result
of deaths avoided were calculated based on the average
life expectancy remaining for each age group and were
derived using life tables for China provided by World
Health Organization estimates [35]. All costs and out-
comes were discounted at a rate of 3 % per year.
Results
The estimated number of pneumococcal disease cases,
pneumococcal related deaths, life years, and quality-
adjusted-life-years by age group predicted by the model
for both the non-vaccination strategy and the strategy
using PCV7 are reported in Table 2. During a normal,
non-pandemic influenza season the model predicted that
114,342 cases of IPD, 1,481,050 cases of in-patient pneu-
monia and 76,714 deaths could be prevented as a result
of routine vaccination with PCV7 among children in
China. The majority of the cases prevented and the
deaths averted were among the unvaccinated population
due to the herd effect of the vaccine. Additionally, the
model predicted that routine vaccination with PCV7
would result in 2,497,176 life years saved and 2,232,520
QALYs gained over the remaining years of life for the in-
dividuals within the model based on outcomes occurring
during a single season.
The estimated cost results are shown in Table 3. The
cost savings from fewer cases of pneumococcal disease
were estimated to be 12.5 billion Yuan (US $1.9 billion),
and the cost of the vaccination program was 43.2 billion
Yuan (US $6.7 billion) resulting in a total direct medical
cost increase of 30.7 billion Yuan (US $4.7 billion) from
the implementation of the vaccination program. The es-
timated cost-per-life-year saved was ¥12,281 (US $1,900)
and the cost-per-QALY gained was ¥13,737 (US $2,125).
During a severe pandemic season, the model predicted
that routine vaccination with PCV7 would result in
2,951,119 fewer cases of IPD, 2,152,519 fewer cases of
in-patient pneumonia, and 707,526 deaths would be
avoided. Approximately 46.3 % of the IPD cases pre-
vented and 42.5 % of the deaths averted were among the
18 to 49 year old age group. The total number of life
years saved and QALYs gained during a severe pandemic
season were estimated to be 34.4 million and 30.5 mil-
lion respectively. The direct medical cost savings were
projected to be 84.2 billion Yuan (US $13.02 billion) as a
result of fewer pneumococcal disease cases and 41.0 bil-
lion Yuan (US $6.34 billion) when the direct costs of the
vaccination program were included. As a result, during a
severe influenza pandemic, routine child vaccination
with PCV7 is predicted to be more effective and less
costly overall relative to the case of no vaccinations
(dominant).
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Sensitivity analyses
A series of univariate sensitivity analyses were performed
in order to test the robustness of the results to several
key data input parameters. These analyses were per-
formed on the level of vaccine coverage (+/− 10 %), the
vaccine price (+/− 10 %), reduction of the indirect (herd)
effects by 50 %, differences in base-line disease incidence
rates (+/− 10 %), and differences in base-line case fatality
rates (+/− 10 %) for both the typical influenza season
and a severe influenza pandemic season. The results re-
garding the estimates for the number of deaths averted,
life years saved, total direct medical costs, and cost-per-
life-years saved from these analyses along with base case
results are provided in Table 4.
Model results during a standard influenza season were
most responsive to changes in the indirect (herd) effects
of the vaccine on the unvaccinated population. When
these effects were reduced by 50 %, the cost-per-life-year
saved increased from a base case value of ¥12,281
(US$1,899) to ¥24,549 (US$3,797). The results were least
sensitive to changes in case fatality rates with a cost-per-
life year saved range of ¥2,480 (US$384) between the
high and low values tested, followed by alterations in the
vaccine price (¥3,419 (US$529)), changes in disease inci-
dence (¥3,482 ($US539)), and changes in the level of
vaccine coverage (¥4,453 (US$689)). During a severe in-
fluenza pandemic the estimates for the number of deaths
averted and the life-years saved were also found to be
most sensitive to changes in the indirect effects of the
vaccine. In all cases, however, the cost-per-life-year saved
results from including PCV7 into the routine vaccin-
ation strategy were found to remain the dominant strat-
egy in the context of a severe influenza pandemic.
Discussion
Several studies have examined both the clinical and eco-
nomic benefits of the PCV7 vaccine in various countries in
Asia [23, 36–39], however very few have specifically esti-
mated the impact or the cost-effectiveness of including
PCV7 into the routine vaccination schedule in China utiliz-
ing local economic and epidemiological data [17, 23, 40].
None of these studies, however, examine the use of PCV7
in the context of influenza. For example, in Che et al., the
authors used a decision-tree model to estimate the impact
of PCV7 in Chinese infants [40]. To our knowledge, there
have been only two other studies that have examined the
use of PCV7 in the context of both a typical influenza sea-
son and a severe pandemic [10, 41]. The existing studies
used a similar theoretical framework with a focus on the
U.S. population. Our study differs in that we focus on the in-
clusion of the PCV7 vaccine in China using, where available,
local epidemiological data and Chinese specific cost data.
According to the World Health Organization’s phar-
macoeconomic evaluation criteria, if the incremental
cost effectiveness ratio is found to be within three times
the per capita income of that region then the interven-
tion would be considered cost-effective [42]. As of 2011,
gross per capita yearly income of China was estimated to
be ¥35,783 (US$5,535) [43]. In all cases, our results were
found to be either cost-saving (dominant strategy) or
within the recommended cost-effectiveness threshold to
be considered a cost-effective intervention. The previous
studies conducted on the U.S. population found the use
of the pneumococcal conjugate vaccine to be a cost-
saving strategy in the context of both a typical influenza
season and a pandemic outbreak [10]. We also found
PCV7 to be a cost-saving vaccine program during a se-
vere influenza pandemic. However, unlike the U.S. stud-
ies, but consistent with a cost-effectiveness analysis of
PCV7 in Shanghai [23], our results in a typical season
were cost-effective, at ¥13,737 (US $2,125) per QALY
saved. The reason for the slight differences likely has to
do with differences in cost data in China, where vaccin-
ation costs are higher and treatment costs are lower than
in the U.S. Note that changing the vaccination schedule
would impact the costs of the program and may alter
the effectiveness of the vaccines.
The study as implemented is subject to a number of po-
tential limitations which may impact the overall results.
The study was conducted from a third party payer perspec-
tive instead of using a societal perspective. As a result, we
do not include the additional costs associated with
pneumococcal morbidity and mortality such as the value of
lost productivity from premature death, caregiver time
costs, and travel costs. Given the estimated number of
deaths averted and IPD cases prevented by the model, the
inclusion of these costs would likely have substantially
added to the potential cost savings from the use of PCV7.
The study used serotype coverage data from a single study
in China, but serotype coverage can vary substantially
across regions and over time [9]. Were we to assume lower
serotype coverage of 60 %, the projected cases averted and
deaths prevented would be slightly lower. However, the
overall conclusion of cost-effectiveness in a typical season
and cost savings in a pandemic influenza season are still
preserved. The disease cost data utilized in the model were
derived from a recent study on the cost-effectiveness of
PCV7 in Shanghai and are based on data from Shanghai
area hospitals [23]. These data may not accurately reflect
the costs associated with inpatient, pneumococcal disease
in China as a whole since treatment options and price levels
likely vary from region to region. We also assumed, consist-
ent with previous literature [10, 14, 15, 17], that the direct
benefits of vaccination begin to wane two years after the
initial dose and that there is no protection beyond the fifth
year after vaccination. As a result, all individuals within the
model five years of age and older are considered unvaccin-
ated. While consistent with previous literature, it is unlikely
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Table 2 Estimated outcomes of disease and mortality by vaccination strategy
Parameter Age group (Years)
0 - < 2 2 - 4 5 - 17 18 - 49 50 - 64 65+ Total
Non-pandemic year
Pneumococcal meningitis (Thousands)
No Vaccination 0.3 0.3 43.0 37.5 5.5 7.3 94.0
Vaccination 0.1 0.1 35.5 23.2 4.5 4.9 68.2
Cases Avoided 0.3 0.2 7.5 14.4 1.0 2.5 25.8
Pneumococcal bacteremia (Thousands)
No Vaccination 0.6 2.6 144.1 118.9 14.8 38.3 319.3
Vaccination 0.1 0.7 118.9 73.4 12.2 25.5 230.8
Cases Avoided 0.5 1.9 25.2 45.5 2.6 12.9 88.6
All-cause pneumonia (Thousands)
No Vaccination 568.6 2090.1 1959.5 1166.0 713.1 3936.9 10434.2
Vaccination 340.9 1531.3 1783.4 1026.1 648.9 3622.5 8953.1
Cases Avoided 227.6 558.8 176.2 139.8 64.2 314.4 1481.1
All-cause otitis media (Thousands)
No Vaccination 2972.6 12476.0 15448.6
Vaccination 2285.9 9704.6 11990.5
Cases Avoided 686.7 2771.4 3458.1
Deaths
No Vaccination 27393 8479 22921 85581 46750 410341 601465
Vaccination 16385 6156 20244 66622 42034 373311 524750
Deaths Avoided 11008 2323 2677 18959 4717 37030 76714
Life Years (Millions)
No Vaccination 1076.3 4194.8 19298.9 31151.6 3715.1 903.1 60339.7
Vaccination 1077.2 4195.0 19299.1 31152.4 3715.2 903.4 60342.2
Life Years Saved 0.9 0.2 0.2 0.8 0.1 0.3 2.5
QALYs (Millions)
No Vaccination 983.7 3829.8 17368.9 26696.9 2998.1 722.4 52599.8
Vaccination 984.6 3829.9 17369.1 26697.6 2998.2 722.7 52602.1
QALYs Gained 0.8 0.2 0.2 0.7 0.1 0.3 2.2
Pandemic year
Pneumococcal meningitis (Thousands)
No Vaccination 0.3 0.3 43.5 38.0 5.5 7.4 95.1
Vaccination 0.1 0.1 35.9 23.4 4.6 4.9 69.0
Cases Avoided 0.3 0.2 7.6 14.5 1.0 2.5 26.1
Pneumococcal bacteremia (Thousands)
No Vaccination 3.7 38.3 6967.3 3541.4 216.6 841.1 11608.4
Vaccination 0.7 9.8 5748.2 2186.7 179.0 558.9 8683.4
Cases Avoided 2.9 28.5 1219.1 1354.7 37.6 282.2 2925.0
All-cause pneumonia (Thousands)
No Vaccination 644.8 3096.9 3669.6 3332.9 855.9 3978.8 15578.8
Vaccination 386.7 2270.8 3371.1 2947.3 779.2 3671.2 13426.3
Cases Avoided 258.1 826.0 298.5 385.6 76.8 307.6 2152.5
All-cause otitis media (Thousands)
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that the direct effectiveness of the vaccine would diminish
to zero and therefore this assumption likely underestimates
the potential benefits of the widespread use of PCV7 in
China over time.
The analysis required extrapolation of several parame-
ters from local and international epidemiologic data to de-
rive necessary age-specific incidence rates. We note that
the process of incorporating data derived from a variety of
outside sources is subject to bias. As such, we included
variations on these data in the sensitivity analyses that
were performed. In all cases the results remained cost-
effective under WHO thresholds of 2–3 times GDP per
capita [42]. Additionally, the estimates regarding the ex-
pected increases in incidence of pneumococcal disease
during a severe pandemic were derived from previously
published estimates and are based on the 1918 pan-
demic [10]. The authors of that study, as do we, ac-
knowledge that the 1918 pandemic was relatively more
severe than subsequent pandemic outbreaks and that
access to care and antibiotics has changed dramatically
over the past century. As such, we regard the severe
pandemic results estimated here for China as a worst
case scenario and that a modern day influenza pan-
demic would fall somewhere within the spectrum of a
typical influenza season and the severe pandemic in
terms of severity of health care outcomes. In all cases,
however, the estimates derived in this study were found
to be cost-effective under the established World Health
Organization guidelines [42].
Conclusions
The PCV7 vaccine is effective in reducing the incidence
of pneumococcal disease in both the vaccinated and un-
vaccinated populations due to herd protection. Given
the link between influenza and mortality due to sec-
ondary pneumococcal infection, it is likely that routine
vaccination with PCV7 would help reduce the morbid-
ity and mortality associated with influenza during both
a typical influenza season and potential severe influ-
enza pandemic. Our model suggests that routine vaccin-
ation with PCV7 among infants in China would prevent
more than 75,000 deaths from secondary pneumococcal in-
fection during a typical influenza season and prevent more
Table 2 Estimated outcomes of disease and mortality by vaccination strategy (Continued)
No Vaccination 2986.2 12348.1 15334.3
Vaccination 2302.9 9665.5 11968.4
Cases Avoided 683.3 2682.6 3365.9
Deaths
No Vaccination 314818 44700 779307 1170382 109165 758160 3176532
Vaccination 187101 28401 652085 869387 95870 636163 2469006
Deaths Avoided 127717 16300 127222 300995 13295 121997 707526
Life Years (Millions)
No Vaccination 1053.2 4192.0 19249.4 31104.0 3713.7 900.1 60212.2
Vaccination 1063.5 4193.2 19257.7 31117.2 3714.0 901.1 60246.7
Life Years Saved 10.3 1.3 8.3 13.2 0.3 1.0 34.4
QALYs (Millions)
No Vaccination 962.6 3827.2 17324.3 26656.0 2997.0 720.0 52487.1
Vaccination 972.0 3828.4 17331.8 26667.4 2997.2 720.9 52517.6
QALYs Gained 9.4 1.2 7.5 11.3 0.2 0.8 30.5
Table 3 Estimated cost (Savings) results
No vaccinations Vaccination Difference
Non-pandemic year
Disease Cost (Millions)
Meningitis 2261.9 1648.1 (613.8)
Bacteremia 7839.5 5685.8 (2153.7)
All-Cause Pneumonia 87443.5 78171.6 (9271.9)
All-Cause otitis media 2136.7 1658.1 (478.5)
Total Disease Costs 99681.6 87163.7 (12517.9)
Vaccination Program 0 43186.4 43186.4
Total Costs 99681.6 130350.1 30668.4
Pandemic year
Disease Cost (Millions)
Meningitis 2287.6 1666.8 (620.8)
Bacteremia 283393.4 212734.7 (70658.7)
All-Cause Pneumonia 115122.6 102649.1 (12473.5)
All-Cause otitis media 2121.3 1655.3 (466.0)
Total Disease Costs 402924.9 318706.0 (84218.9)
Vaccination Program 0 43186.4 43186.4
Total Costs 402924.9 361892.4 (41032.5)
All values measured in 2011 Chinese Yuan
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than 700,000 deaths and save more than 41 billion Yuan
(US$6.3 billion) during a severe influenza pandemic. Given
the differences in population size and cost of medical
treatment, these values are consistent with previously
published estimates regarding the U.S. during a severe
pandemic (108,500 deaths averted and $7.34 billion in
cost savings) [10]. It is likely, therefore, that the inclusion
of PCV7 vaccine into the routine vaccination schedule of
China would be a cost-effective intervention in the con-
text of an influenza outbreak.
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